 The FDA has granted Rare Pediatric Disease status to Chinook Therapeutics Incs NASDAQ: KDNY CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A for primary hyperoxaluria PH, a rare genetic disorder that mainly affects the kidneys and results from a buildup of a substance called oxalate. 